RM
Rachel McMinn (Chief Executive Officer) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Neurogene Inc. (NGNE). Across 1 priced purchase filing, the average 21-session return was +45.3% from execution and +7.5% from disclosure (delay-adjusted; derived). The largest single filing was $969K of NGNE (47,500 sh × $20.40, as filed), executed Nov 22 2024. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+45.3%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+7.5%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
3d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
–
no filings in the window
Last traded
Nov 22 2024
Filed Nov 25 2024
Median ADV $7.6M across their filed names
Open performance→Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 24 months
Most traded names
NGNERecent filings
NGNEPURCHASE
Neurogene Inc.
View filing →
$969K47,500 sh × $20.40
Exec Nov 22 2024
Filed Nov 25 2024 · 5:30 PM ET